Two years after a big scientific swing nearly pushed Biogen to the brink, CEO Christopher Viehbacher is embarking on a corporate rethink, one that balances Biogen’s characteristic risky bets with a frank commitment to pragmatism.
Speaking at the STAT Summit in Boston on Thursday, Viehbacher said his Biogen predecessors fell off track through a few unsound investments and an all-or-nothing bet on Aduhelm, the Alzheimer’s disease treatment that became a pharmaceutical cautionary tale. Viehbacher, one year into his tenure at the storied company, said Biogen’s future will rely on taking a more disciplined approach to risk.
“There’s a huge amount of pride inside the company that we go after problems other people don’t,” Viehbacher said, “but at the end of the day you also have to get medicines through the pipeline to benefit patients, and that’s why we’re expanding the aperture of what we’re doing in R&D.”
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect